Physician profile
Paul Markowski
NPI 1679930994
$1,184.79
in general payments reported to CMS, 2019-2025
26 companies · $577 in 2025
The $577 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $174 · 2021: $28.95 · 2022: $23.79 · 2023: $51.84 · 2024: $113 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $655 · Education: $87.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $654.95 |
| Education | $87.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $219.04 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $152.39 | 2019-2025 | Reblozyl, Opdualag |
| Daiichi Sankyo INC. | $119.17 | 2020-2025 | Enhertu, Datroway |
| Janssen Biotech, INC. | $102.39 | 2020-2025 | Carvykti, Darzalex, Talvey |
| Celgene Corporation | $76.51 | 2019-2025 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $61.21 | 2019-2025 | Fruzaqla |
| Merck Sharp & Dohme LLC | $49.04 | 2019-2025 | Keytruda |
| Astrazeneca Pharmaceuticals Lp | $43.35 | 2020-2025 | |
| Lilly USA, LLC | $42.33 | 2019-2020 | |
| Abbvie INC. | $27.77 | 2021-2025 | |
| Amgen INC. | $26.53 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.00 | 2025 | |
| Menarini Silicon Biosystems, INC. | $24.22 | 2025 | Cellsearch |
| Legend Biotech USA INC. | $21.67 | 2024 | |
| Caris Mpi, INC. | $21.55 | 2025 | Mi Cancer Seek |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $21.30 | 2025 | Clonoseq |
| Genentech USA, INC. | $20.61 | 2025 | Tecentriq |
| Pharmacosmos Therapeutics INC. | $19.07 | 2024 | Monoferric |
| Pharmacyclics LLC, An Abbvie Company | $16.54 | 2023 | Epkinly, Imbruvica |
| Foundation Medicine, INC. | $14.99 | 2020 | |
| Taiho Oncology, INC. | $14.84 | 2019 | |
| Eisai INC. | $14.30 | 2019 | |
| Tesaro, INC. | $13.77 | 2019 | |
| Pfizer INC. | $13.72 | 2019 | |
| Seagen INC. | $12.22 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Markowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.